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Abstract
Summary Treatment effects over 2 years of teriparatide vs.
ibandronate in postmenopausal women with osteoporosis
were compared using lumbar spine bone mineral density
(BMD) and trabecular bone score (TBS). Teriparatide induced
larger increases in BMD and TBS compared to ibandronate,
suggesting amore pronounced effect on bonemicroarchitecture
of the bone anabolic drug.
Introduction The trabecular bone score (TBS) is an index of
bone microarchitecture, independent of bone mineral density
(BMD), calculated from anteroposterior spine dual X-ray
absorptiometry (DXA) scans. The potential role of TBS for
monitoring treatment response with bone-active substances is
not established. The aim of this study was to compare the
effects of recombinant human 1–34 parathyroid hormone
(teriparatide) and the bisphosphonate ibandronate (IBN), on
lumbar spine (LS) BMD and TBS in postmenopausal women
with osteoporosis.
Methods Two patient groups with matched age, body mass
index (BMI), and baseline LS BMD, treated with either daily
subcutaneous teriparatide (N=65) or quarterly intravenous
IBN (N=122) during 2 years and with available LS BMD
measurements at baseline and 2 years after treatment initiation
were compared.
Results Baseline characteristics (overall mean ± SD) were
similar between groups in terms of age 67.9±7.4 years, body
mass index 23.8±3.8 kg/m2, BMD L1–L4 0.741±0.100 g/
cm2, and TBS 1.208±0.100. Over 24 months, teriparatide
induced a significantly larger increase in LS BMD and TBS
than IBN (+7.6 %±6.3 vs. +2.9 %±3.3 and +4.3 %±6.6 vs. +
0.3 %±4.1, respectively; P<0.0001 for both). LS BMD and
TBS were only weakly correlated at baseline (r2=0.04) with
no correlation between the changes in BMD and TBS over
24 months.
Conclusions In postmenopausal women with osteoporosis, a
2-year treatment with teriparatide led to a significantly larger
increase in LS BMD and TBS than IBN, suggesting that
teriparatide had more pronounced effects on bone
microarchitecture than IBN.
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Introduction
Osteoporosis and osteoporosis-related fractures represent a
worldwide disease burden, especially in North America and
Europe [1–5]. With much of this burden stemming from the
morbidity and mortality related to the roughly nine million
osteoporotic fractures that occur each year [4, 5], the primary
goal of treatment has long been fracture prevention [6–8].
As recommended by the World Health Organization
(WHO) since 1994 [9], bone mineral density (BMD), mea-
sured by dual X-ray absorptiometry (DXA) is the current gold
standard for diagnosing osteoporosis and monitoring treat-
ment, supported by the fact that BMD is a major determinant
of bone strength and fracture risk [10]. However, considerable
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overlap exists between BMD values in individuals who de-
velop fractures and those who do not [11], indicating that
other factors influence both bone strength and fracture risk.
To cite just but a few: macrogeometry of cortical bone,
microarchitecture of trabecular bone, as well as bone
microdamage, mineralization, and turnover [12–14].
The trabecular bone score (TBS) is derived from a simple
anteroposterior LS DXA scan and can be used for the nonin-
vasive assessment of intravertebral cancellous bone
microarchitecture [15–18]. The TBS was shown to discrimi-
nate between patients with incident hip, nonvertebral, or ver-
tebral fracture and nonfractured patients with osteoporosis in
several prospective and retrospective cohort studies [19–24],
with odds ratios ranging between 1.6 and 2.05 with a similar
order of magnitude than lumbar spine BMD [19, 21, 22, 24].
In addition, in these studies, the combination of TBS and
lumbar spine BMD (LS BMD) was generally superior to
either measurement alone with regard to fracture risk predic-
tion [19, 20, 22–24]. Furthermore, the TBS was responsive to
treatment with antiresorptive drugs in a large cohort study [25]
and in the retrospective analysis of a randomized placebo-
controlled trial with the aminobisphosphonate zoledronate
[26].
Daily subcutaneous injections of recombinant human 1–
34 N-terminal fragment of parathyroid hormone (teriparatide)
were shown to increase BMD and to reduce the risk of new
vertebral and nonvertebral, but not hip, fractures in patients
with postmenopausal and glucocorticoid-induced osteoporo-
sis [27, 28]. The observed increases in LS BMD with
teriparatide accounted for approximately 30–41 % of the
achieved vertebral fracture risk reduction, suggesting other
mechanisms accounting for the remainder [27, 29].
Teriparatide was recently shown to improve trabecular
microarchitecture in iliac crest bone biopsies of postmeno-
pausal women [29], confirming earlier preclinical data show-
ing improved histomorphometric cancellous bone parameters
and vertebral bone strength in ovariectomized rats [30] and
monkeys [31]. The effects of teriparatide on the TBS are
unknown.
Bisphosphonates, such as the aminobisphosphonate
ibandronate (IBN), are inhibitors of bone resorption belonging
to the mainstay of osteoporosis treatment. Histomorphometric
data in postmenopausal women treated during 2 years with
intravenous ibandronate showed no increase in trabecular
number or volume and no decrease in intertrabecular separa-
tion [32]. In line with these findings, an earlier study per-
formed with the intravenous aminobisphosphonate
zoledronate in postmenopausal women showed an only mod-
est increase in TBS consistent with a preservation of vertebral
bone microarchitecture [26].
The aims of this study were: (1) to compare the effects of
subcutaneous teriparatide and intravenous ibandronate on LS
BMD and TBS in postmenopausal women with osteoporosis;
(2) to assess whether the changes in TBS are independent of
those of BMD; and (3) to evaluate the changes in TBS in
terms of possible clinical relevance at the individual patient
level.
Methods
The study was conducted at the Department of Osteoporosis
of the University Hospital of Berne, Switzerland as an open-
label, retrospective, nonrandomized, treatment-controlled
study comparing the effects of an up to 2-year treatment with
subcutaneous teriparatide (Forsteo®, Eli Lilly, USA) vs. a 2-
year treatment with intravenous IBN (Bonviva®, Roche,
Switzerland) on LS BMD and TBS in two groups of post-
menopausal women with osteoporosis matched for age, body
mass index (BMI), and LS BMD.
Study population and treatment schemes
Postmenopausal women with primary osteoporosis referred
for evaluation to the osteoporosis consultation of the Depart-
ment of Osteoporosis of University Hospital of Berne, Swit-
zerland, between 2007 and 2009, who were subsequently
treated with teriparatide 20 μg self-injected daily, were eval-
uated if they had LS BMDmeasurements performed by DXA
at baseline and after 2 years of therapy (n=70).Women treated
with teriparatide usually had experienced a vertebral fragility
fracture during a prior therapy with an antiresorptive, inde-
pendently of their LS BMD value. The reimbursed duration of
treatmentwith teriparatidewas increased from18 to 24months
during the course of the study. As a consequence, one sixth of
the patients treated with teriparatide were treated during
18 months followed by an intravenous infusion of zoledronate
5 mg, the other five sixth were on teriparatide during
24 months. The control group consisted of postmenopausal
women with primary osteoporosis in whom a treatment with
intravenous ibandronate 3 mg every 3 months was initiated
between 2007 and 2009 and monitored during at least two
following years at the Department of Osteoporosis of Berne.
Women treated with ibandronate usually had a BMD T-score
at or below −2.5 or one or more prevalent vertebral fractures.
Women on ibandronate were matched for age, BMI, and LS
BMD with women in the teriparatide group, following a 2:1
ratio (n=140). All subjects were vitamin D-replete and re-
ceived adequate calcium and vitamin D3 supplementation.
Women currently on glucocorticosteroids or presenting other
secondary forms of osteoporosis were not eligible. Prior ther-
apies with bisphosphonates, estrogens, or other bone active
substances including vitamin D were allowed. Only women
with evaluable DXA scans for both LS BMD and TBS at
baseline and after 2 years in the teriparatide and the
ibandronate groups, respectively, were included in the analysis.
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Measurement of bone mineral density
Bone mineral density (BMD) was assessed by DXA (Hologic
QDR 4500A®, Hologic, Bedford, MA, USA) at the single
study centre of the Department of Osteoporosis of the Univer-
sity Hospital of Berne, Switzerland. All DXA scans were
performed in accordance with manufacturer recommendations.
Lumbar spine BMD measurements were recorded for L1
through L4 (L1−L4). BMDwas expressed as grams per square
centimeter of hydroxyapatite and as T-scores (standard devia-
tion [SD] from the mean of a healthy young female popula-
tion). The manufacturer’s normative database was used as
reference for the LS after analysis according to International
Society for Clinical Densitometry (ISCD) rules [33]. Individ-
ual vertebrae were excluded in case of fractures or degenerative
changes, in accordance with ISCD rules for individual verte-
brae exclusion (more than 1 standard deviation from immedi-
ately adjacent vertebrae). Quality control was performed daily
(anthropometric spine phantom supplied by the manufacturer).
Measurement of trabecular bone score
The trabecular bone score (TBS) is a grey-level texture mea-
surement that can be applied to DXA images for quantifying
local variations in grey level [15–17]. Using experimental
variograms of two-dimensional (2D) projection images, TBS
can differentiate between three-dimensional (3D) microstruc-
tures that exhibit the same bone density, but different trabecular
characteristics [15, 18]. The TBS is obtained by direct
(re-)analysis of an acquired lumbar spine DXA image, without
need for further imaging. All TBS determinations were per-
formed in a blindedmanner within the BoneDisease Unit at the
University Hospital of Lausanne, Lausanne, Switzerland using
TBS iNsight® Software version 1.8.2 (Med-Imaps, Bordeaux,
France). Lumbar spine TBS (LS TBS) was evaluated in the
same vertebrae and regions of measurement as those used for
LS BMD, with LS TBS calculated as the mean value of the
individual measurements for vertebrae L1−L4. The coefficient
of variation for LS BMD measurements at the Department of
Osteoporosis of the University Hospital of Berne is 0.90 %
when applying with ISCD recommendations (15 outpatients
representative of our daily routine with triplicate measurements
after repositioning) with a corresponding coefficient of varia-
tion of 1.12 % for TBS. Thus, the least significant change
(LSC) is 2.49 % for LS BMD and 3.10 % for TBS.
Statistical analysis
Descriptive analysis included means and percentages with
standard deviations. The percent changes in BMD and TBS
were calculated for each subject as the absolute change from
baseline to 2-year follow-up, divided by the baseline value.
Bivariate intergroup comparisons were performed between
those treated with IBN vs. teriparatide using Student’s t tests
and Pearson χ2 analysis for continuous and noncontinuous
variables, respectively. Pearson correlation coefficients were
calculated for BMD vs. TBS and for change from baseline in
BMD vs. change from baseline in TBS. All inferential tests
were two-tailed and P<0.05 was set as the threshold for
statistical significance. All statistical analyses were performed
using Stata® software (Version 12, StataCorp, Texas, USA).
Results
Overall, 65 (93 %) and 122 (87 %) patients had evaluable
DXA scans for LS BMD and TBS at baseline and after 2 years
in the teriparatide and the ibandronate groups, respectively,
and were included in the analysis. In total, 40, 40, and 20 % of
the patients had four, three, and two vertebrae evaluated, respec-
tively. As a result of matching, baseline characteristics (mean
±SD) were similar between groups in term of age, body mass
index, baseline LS BMD T-score and LS TBS (Table 1).
Patients in the teriparatide group were more likely having
had prior therapy with a bisphosphonate (95.4 vs. 80.3 %,
P=0.005), having prevalent vertebral fractures or a positive
history of fracture during adulthood (90.5 vs. 44.3, and 73.8
vs. 41.0 %, respectively; P=0.0001 for both), and had a
significantly higher clinical fracture risk score for hip and
major osteoporotic fractures assessed by FRAX®.
As shown in Fig. 1, after 24 months of therapy, LS BMD
and TBS increased significantly more with teriparatide com-
pared to IBN (+7.6 %±6.3 vs. +2.9 %±3.3 and +4.3 %±6.6
vs. +0.3 %±4.1, respectively; P<0.0001 for both). Compared
to baseline, increases in LS BMD were significant in both the
teriparatide and IBN group (P<0.0001 for both), while in-
creases in LS TBS were significant in the teriparatide group
only (P<0.0001).
Baseline spine BMD and TBS were only weakly correlat-
ed, (r2=0.04), indicating that only 4 % of the variance in one
parameter was explained by the other. There was no correla-
tion between the 2-year changes in BMD and TBS from
baseline (r2=0.01).
As shown in Table 2, LS BMDwas more sensitive than LS
TBS with regard to the proportion of patients achieving an
increase above least significant change (LSC) in both treat-
ment groups: 78.5 vs. 61.5 % (McNemar test P<0.01) and
51.6 vs. 26.3 % (P<0.001) with teriparatide and IBN, respec-
tively. Interestingly, while only 11.0 % of the patients did not
respond in terms of TBS below the LSC with teriparatide, this
proportion reached 27.0 % with IBN. Furthermore, in the
teriparatide group, 51.0 % of the patients were above
the LSC for both LS BMD and TBS vs. only 28.0 % in
the IBN group (results not shown in Table 2), suggest-
ing a stronger effect on bone microarchitecture with the
former.
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Discussion
In postmenopausal women with primary osteoporosis, a 2-
year treatment with teriparatide increased LS BMD and TBS
significantly more and in a significantly greater proportion of
patients than a 2-year treatment with intravenous ibandronate.
As the increase in LS TBS was largely independent from the
BMD response, these results suggests that LS TBS may
contribute to assess the effects of bone anabolic agents on
vertebral microarchitecture.
Only few studies have investigated the effect of bone active
substances on LS TBS [25, 26]. Taken together with the
Table 1 Baseline Demographics
and Clinical Characteristics
(mean ± SD)
All values are means ± SD, except
indicated otherwise
Teriparatide group IBN group P value
N 65 122
Duration of active treatment (months) 22.9±3.6 24.0±4.7 0.10
Age (years) 68.9±9.0 67.4±6.5 0.20
BMI (kilogram per square meter) 23.7±4.2 23.8±3.5 0.92
Prior therapy with an oral/IV bisphosphonate (percent) 95.4 80.3 0.005
Duration of washout prior to study drug initiation (months) 0.23±0.79 0.26±0.85 0.23
Lumbar spine
BMD (gram per square centimeter) 0.759±0.153 0.732±0.080 0.12
T-score −2.66±1.35 −2.77±0.67 0.46
TBS 1.206±0.100 1.209±0.100 0.85
Total hip
BMD (gram per square centimeter) 0.703±0.113 0.729±0.100 0.10
T-score −1.96±0.93 −1.75±0.78 0.11
Femoral neck
BMD (gram per square centimeter) 0.606±0.105 0.622±0.084 0.27
T-score −2.09±1.17 −2.11±0.81 0.91
Prevalent vertebral fractures (percent) 90.5 44.3 0.0001
Positive history of nonvertebral fractures during
adulthood (percent)
73.8 41 0.0001
Past use of glucocorticosteroids (percent) 9.0 % 4.6 % 0.28
10-year absolute risk for major osteoporotic fractures
(FRAX® with BMD, percent)
26.7±10.4 21.1±10.1 0.0001
10-year absolute risk for hip fractures
(FRAX® with BMD, percent)
8.15±6.7 5.1±5.1 0.0001
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present findings, these earlier reports are consistent with the
concept that bisphosphonates allow for “positive mainte-
nance” of bonemicroarchitecture rather than a major improve-
ment in microarchitecture. For almost two decades,
bisphosphonates have been the therapy of choice to treat
osteoporosis and to prevent fractures, relying on solid evi-
dence with regard to fracture risk reduction [2, 34–38]. How-
ever, the long-term bone safety of bisphosphonates has been
recently questioned [39]. On one hand, bisphosphonates in-
crease bone strength by increasing the mineralization of
remodelled bone units, reducing cortical porosity and decreas-
ing focal stress. On the other hand, they suppress the genera-
tion of new bone remodelling units and reduce bone turnover
[39]. In the present study, the increase in LS BMD and TBS
observed with IBN was of a lower order of magnitude than
expected. In earlier studies, LS TBS increased by 0.25 to
0.5 % per year under antiresorptive therapy [25, 26], which
is clearly more than the 0.3 % over 2 years reported in the
present study. One of the possible explanations may be related
to the fact that more than 80 % of the “real life” women
included had been on bisphosphonate therapy before being
switched to intravenous ibandronate after a very short or no
washout period. This suggests not unexpectedly that, in pa-
tients under prior antiresorptive therapy, bisphosphonates may
be more likely to maintain than to restore vertebral
microarchitecture.
Teriparatide exerts primarily bone anabolic effects, which
include increasing cancellous bone volume and connectivity,
increasing cortical bone thickness, and enhancing trabecular
morphology [39, 40]. Since the inaugural publication by Neer
et al. [27] in 2001, several smaller studies have confirmed that
teriparatide allows for strong BMD increases and for fracture
risk reduction, suggesting that it may become an attractive
alternative to bisphosphonates for strengthening and possibly
restoring bonemicroarchitecture [41–44]. In the present study,
a 2-year therapy with subcutaneous teriparatide induced a
statistically significant increase in LS BMD and TBS of large
magnitude. The latter (+4.3 % in only 2 years) exceeds by far
the TBS increases reported with antiresorptive substances to
date [25, 26]. Furthermore, the ratio of BMD to TBS increase
was approximately 2:1 with teriparatide and 9:1 with
ibandronate in the present study, compared to 10:1 with
bisphosphonates in a retrospective study of 534 postmeno-
pausal women treated with antiresorptive therapy in the Ca-
nadian province of Manitoba [25], and 4:1 in a 3-year ran-
domized, controlled study with yearly intravenous
zoledronate [26]. Taken together with the absence of a signif-
icant correlation between changes from baseline in BMD and
changes from baseline in TBS [25, 26], these observations
indicate that BMD and TBS measure different characteristics
of bone and bone strength.
With regard to individual therapy monitoring, only 12–
35 % of patients on bisphosphonates had an increase in TBS
that was exceeding the LSC in earlier studies [25, 26], as
compared to 26 % in the present analysis. In contrast, about
62% of the patients on teriparatide were above LSC, primarily
indicating that LS TBS may be more suitable for monitoring
the effects of bone anabolic substances than for monitoring the
effects of antiresorptives.
To date, only one direct comparison between teriparatide
and a bisphosphonate (risedronate) has been published in
postmenopausal women with osteoporotic spine compression
fractures. In that study, teriparatide yielded a significantly
greater increase in BMD from baseline in the lumbar spine
and femoral neck and was associated with a lower incidence
of vertebral fractures at 18 months (4 vs. 9 %, respectively;
P=0.01) and with less severe vertebral fractures (P=0.04)
[45]. There have, on the other hand, been several studies
assessing the effects of teriparatide in patients in whom bis-
phosphonate treatment has failed or otherwise been terminat-
ed. In the most recently published study, postmenopausal
women with severe osteoporosis who had failed treatment
with a bisphosphonate responded well to 18 months of treat-
ment with daily parathyroid hormone, with a 37 % reduction
in the incidence of fractures in their second year of treatment
relative to their first 6 months of therapy, and a 76% reduction
relative to baseline subsequent to this. Patients also reported
reduced back pain and improved health-related quality of life
while taking teriparatide [46]. These results are consistent
with the results of several prior studies demonstrating some
benefit of parathyroid hormones in the aftermath of bisphos-
phonate therapy [41, 44, 47] although it is the first time that
results are reported with TBS.
The findings of the present study are limited by the retro-
spective nature of the analysis. Pretreatment with
antiresorptives may have partially blunted some of the expect-
ed effects on LS BMD and TBS. In addition, the two groups
were not comparable with respect to osteoporosis severity,
which may have influenced the results. Keeping these limita-
tions in mind, the results show, for the first time, that larger
Table 2 Percentage of patients above, within and below the LSC for both
teriparatide and IBN groups and LS BMD and LS TBS
Above LSC
(percent)
Within LSC
(percent)
Below LSC
(percent)
Teriparatide
LS BMD 78.5 20.0 1.5
LS TBS 61.5 27.7 10.8
Ibandronate
LS BMD 51.6 42.6 5.8
LS TBS 26.3 46.7 27.0
LSC least significant change, LS lumbar spine
Within LSC for LS BMD is between −2.49 and +2.49 %
Within LSC for LS TBS is between −3.10 and +3.10 %
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effects on trabecular microarchitecture assessed by TBS may
be expected when using bone anabolic substances and may
open the way for future research in this direction including,
but not limited to, the place of TBS alone and/or in combina-
tion with BMD and/or clinical risk factors for the choice and
monitoring of treatments with bone-active substances and the
identification of more individualized treatment schemes for
patients with osteoporosis at increased risk of fracture.
Conclusions
In women with postmenopausal osteoporosis, a 2-year treat-
ment with teriparatide exerted more beneficial effects on
lumbar spine BMD and microarchitecture assessed by TBS
than ibandronate. Changes in LS BMD and TBS from base-
line were not correlated, confirming that these two parameters
measure different responses of bone to therapy. At the indi-
vidual patient level, TBS was significantly more sensitive to
bone anabolic substances than to antiresorptives, with almost
two thirds of the patients on teriparatide showing TBS in-
creases above the least significant change.
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